Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06627647
Title	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Recruitment	Not yet recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-squamous non-small cell carcinoma
Therapies	AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG